New hope for pancreatic cancer: experimental drug combo enters large trial

NCT ID NCT07490301

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 14 times

Summary

This large Phase 2/3 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to standard chemotherapy (FOLFOX) can help people with metastatic pancreatic cancer live longer or shrink their tumors. About 900 participants will be randomly assigned to receive either the new combination or standard care. The study is currently recruiting at sites worldwide.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: telisotuzumab adizutecan (an investigational antibody-drug conjugate) combined with FOLFOX chemotherapy
What this could lead to: If successful, this could offer a new first-line treatment option for metastatic pancreatic cancer, potentially improving response rates and survival.
What could go wrong: This is an early-to-mid stage trial; the drug is investigational and may not work better than standard care. Side effects from the combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA PDAC

Contacts and locations

Locations

Austin Hospital /ID# 280283
RECRUITING

Melbourne, Victoria, 3084, Australia
Azienda Ospedaliero Universitaria Pisana /ID# 285773
NOT_YET_RECRUITING

Pisa, 56126, Italy
Cancer And Hematology Centers Of Western Michigan - Grand Rapids /ID# 279853
RECRUITING

Grand Rapids, Michigan, 49503, United States
China Medical University Hospital /ID# 279725
RECRUITING

Taichung, 40447, Taiwan
City Of Hope - Chicago /ID# 279814
RECRUITING

Zion, Illinois, 60099, United States
Fiona Stanley Hospital /ID# 280079
NOT_YET_RECRUITING

Murdoch, Western Australia, 6150, Australia
Hadassah Medical Center-Hebrew University /ID# 279411
RECRUITING

Jerusalem, 91120, Israel
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 279735
RECRUITING

Kaohsiung City, 807, Taiwan
Monash Health - Monash Medical Centre - Clayton /ID# 280076
NOT_YET_RECRUITING

Clayton, Victoria, 3168, Australia
Oxford University Hospital NHS Trust /ID# 279764
RECRUITING

Oxford, Oxfordshire, OX3 7LE, United Kingdom
Prince Of Wales Hospital - Randwick /ID# 280085
NOT_YET_RECRUITING

Randwick, New South Wales, 2031, Australia
Rambam Health Care Campus- Haifa /ID# 279409
RECRUITING

Haifa, 3109601, Israel
Seoul National University Hospital /ID# 280191
RECRUITING

Seoul, Seoul Teugbyeolsi, 03080, South Korea
Taipei Veterans General Hospital /ID# 279726
RECRUITING

Taipei, 112, Taiwan
Tamworth Hospital /ID# 280099
NOT_YET_RECRUITING

North Tamworth, New South Wales, 2340, Australia
Tel Aviv Sourasky Medical Center /ID# 279414
RECRUITING

Tel Aviv, Tel Aviv, 6423906, Israel
Texas Oncology - Northeast Texas /ID# 280417
RECRUITING

Tyler, Texas, 75702, United States
The Cancer Institute Hospital Of JFCR /ID# 280140
RECRUITING

Koto-ku, Tokyo, 135-8550, Japan
The Chaim Sheba Medical Center /ID# 279408
RECRUITING

Ramat Gan, Tel Aviv, 5265601, Israel
University of Chicago Medical Center /ID# 279460
RECRUITING

Chicago, Illinois, 60637, United States
Virginia Cancer Specialists - Fairfax /ID# 280415
RECRUITING

Fairfax, Virginia, 22031, United States
Washington University /ID# 279890
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.